At least in this ex vivo model, the cytotoxicity kinetics suggest that CD4+ T cells may contribute to tumor cell killing over a longer period and potentially with higher specificity compared to conventional CD8+ CTLs. The gene discussed is CD4; the disease is neoplasm.